Trials / Completed
CompletedNCT00143117
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 460 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UK-390,957 |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2005-09-02
- Last updated
- 2012-11-07
Locations
51 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00143117. Inclusion in this directory is not an endorsement.